Emu Pivotal Validation Trial Commences
Filed with ASX · · 5 pages · English
Summary by 6ix AI
EMVision Medical Devices Ltd. has announced the commencement of the EMU Pivotal Validation Trial for its emu™ bedside brain scanner, aimed at supporting FDA clearance. The trial will take place at multiple sites, including The Royal Melbourne Hospital in Australia and the University of Texas Health Science Center in the US.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
EMvision Medical Devices Ltd. on 6ix
Story so far
Earlier from EMvision Medical Devices
- First Responder Scanner in Successful Aeromedical Testing
- S&P DJI Announces March 2025 Quarterly Rebalance
- EMVision Releases its FY25 Half Yearly Report
- US Ethics Approval Received for Pivotal Validation Trial
- EMVision Receives $2.12m R&D Tax Rebate
Later from EMvision Medical Devices
- Activation of Second US Pivotal Trial Site, Mayo Clinic
- Enhanced Algorithm Performance From Continuous Innovation
- Additional Pivotal Trial Site Activations
- EMVision Awarded $5m Non-Dilutive Government Grant
- Key Developments in Pivotal Trial & Innovation Study
Follow EMvision Medical Devices into a list and get an email when it puts out news.
Follow EMvision Medical Devices